De-escalating treatment in the adjuvant setting in HER2-positive breast cancer-Reference-Cited by-同舟云学术

De-escalating treatment in the adjuvant setting in HER2-positive breast cancer

Published:2018-04 Issue:10 Volume:14 Page:937-945
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Barroso-Sousa Romualdo¹²,Exman Pedro¹²,Tolaney Sara M¹²

Affiliation:

1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA

2. Harvard Medical School, Boston, MA 02115, USA

Abstract

The decision to offer adjuvant therapy to patients with early-stage cancer relies on factors related to the risk of disease recurrence, degree of benefit with the proposed therapy and the associated risk of toxicities. For patients with stages II and III HER2-positive breast cancer, administering 1 year of trastuzumab plus comprehensive chemotherapy is the standard of care. However, the pivotal adjuvant trials had very few older patients and patients with small HER2-positive tumors. In this review, we will discuss the clinical data regarding strategies to de-escalate adjuvant systemic therapy in patients with early stage HER2-positive disease.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2017-2500

Reference48 articles.

1. Global cancer statistics

2. Cancer treatment and survivorship statistics, 2012

3. Characteristics of HER2-positive breast cancer diagnosed following the introduction of universal HER2 testing

4. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

5. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial;npj Breast Cancer;2022-02-16

2. Optimum duration of adjuvant trastuzumab in treatment of human epidermal growth factor receptor-2 positive early breast cancer: protocol for a network meta-analysis of randomised controlled trials;BMJ Open;2020-11

3. Advances in EGFR/HER2-directed clinical research on breast cancer;Advances in Cancer Research;2020

4. GRB7 dependent proliferation of basal‐like, HER‐2 positive human breast cancer cell lines is mediated in part by HER‐1 signaling;Molecular Carcinogenesis;2019-01-28